What is the Lisata Therapeutics Inc. stock price forecast?

Lisata Therapeutics Inc. is currently trading at $3.49. View real-time AI analysis on Alpha Lenz.

What is Lisata Therapeutics Inc. insider trading activity?

View the latest insider trading data for Lisata Therapeutics Inc. on Alpha Lenz.

What is Lisata Therapeutics Inc.'s P/E ratio?

Lisata Therapeutics Inc.'s P/E ratio is -1.8.

Lisata Therapeutics Inc.

NASDAQ · LSTA

$3.49+0.04(+1.16%)Pre-market

Ask about Lisata Therapeutics Inc.'s future dividend policy...

Alpha Chat Insight

“Lisata Therapeutics Inc. trades at a P/E of -1.8 (undervalued) with modest ROE of -74.7%.”

Ask for details →

Company Overview

Lisata Therapeutics Inc. is an innovative biotechnology company specializing in the development of advanced therapies aimed at capitalizing on the body’s own inherent capabilities to combat serious diseases. The primary focus of the company is to harness cutting-edge research in cell therapy to address cardiovascular diseases and other critical conditions. Noteworthy for its dedication to scientific advancement, Lisata Therapeutics leverages both proprietary and collaborative research to uncover breakthrough treatments. Based in the burgeoning biotech landscape, the company operates at the intersection of healthcare and technology, providing potentially transformative solutions that impact sectors including cardiology and regenerative medicine. This emphasis positions Lisata Therapeutics as a significant player in the bio-pharmaceutical market, contributing to future medical advancements.

CEODr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D.

Websitehttps://www.lisata.com

SectorHealthcare

IndustryBiotechnology

Employees26

Company Statistics

FY 2025

Profile

$30.32MMarket Cap

$170.00KRevenue

0.00Shares Out

26Employees

Margins

N/AGross

-11099.41%EBITDA

-10711.18%Operating

-10322.35%Pre-Tax

-9756.47%Net

Valuation

-1.83P/E

2.04P/B

178.34EV/Sales

-0.75EV/EBITDA

-1.90P/FCF

Growth (CAGR)

N/ARev 3Yr

N/ARev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-62.89%ROA

-74.67%ROE

-69.04%ROIC

Financial Health

$15.96MCash & Cash Equivalents

$-12.81MNet Debt

21.53%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Lisata Therapeutics Inc. trades at a P/E of -1.8 (undervalued) with modest ROE of -74.7%.”

Ask for details →

Frequently Asked Questions

Lisata Therapeutics Inc. (ticker: LSTA) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 26 employees. Market cap is $30M.

The current price is $3.49 with a P/E ratio of -1.83x and P/B of 2.04x.

ROE is -74.67% and operating margin is -10711.18%. Annual revenue is $170,000.